标题:A(2B) Adenosine Receptor Antagonists with Picomolar Potency
作者:Jiang, Jie; Seel, Catharina Julia; Temirak, Ahmed; Namasivayam, Vigneshwaran; Arridu, Antonella; Schabikowski, Jakub; Baqi, Younis; Hinz 更多
作者机构:[Jiang, Jie; Seel, Catharina Julia; Temirak, Ahmed; Namasivayam, Vigneshwaran; Arridu, Antonella; Schabikowski, Jakub; Hinz, Sonja; Hockemeyer, Joerg; 更多
通讯作者:Muller, CE
通讯作者地址:[Muller, CE]Rheinische Friedrich Wilhelms Univ, Pharmaceut Inst, PharmaCtr Bonn, Pharmaceut Chem 1, Immenburg 4, D-53121 Bonn, Germany.
来源:JOURNAL OF MEDICINAL CHEMISTRY
出版年:2019
卷:62
期:8
页码:4032-4055
DOI:10.1021/acs.jmedchem.9b00071
摘要:The A(2B) adenosine receptor (A(2B)AR) was proposed as a novel target for the (immuno)therapy of cancer since A(2B)AR blockade results in antiproliferative, antiangiogenic, antimetastatic, and immunostimulatory effects. In this study, we explored the structure-activity relationships of xanthin-8-yl-benzenesulfonamides mainly by introducing a variety of linkers and substituents attached to the sulfonamide residue. A new, convergent strategy was established, which facilitated the synthesis of the target compounds. Many of the new compounds exhibited subnanomolar affinity for the A(2B)AR combined with high selectivity. Functional groups were introduced, which will allow the attachment of dyes and other reporter groups. 8-(4((4-(4-Bromophenyl)piperazin-1-yl)sulfonyl)phenyl)-1-propylxanthine (34, PSB-1901) was the most potent A(2B)-antagonist (K-i 0.0835 nM, K-B 0.0598 nM, human A(2B)AR) with >10 000-fold selectivity versus all other AR subtypes. It was similarly potent and selective at the mouse A(2B)AR, making it a promising tool for preclinical studies. Computational studies predicted halogen bonding to contribute to the outstanding potency of 34.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064992520&doi=10.1021%2facs.jmedchem.9b00071&partnerID=40&md5=de916ef39803b4a5d1203e995e292df3
TOP